Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental antibody takes aim at eye inflammation

NCT ID NCT07218770

Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 18, 2026 · Updated 2 times

Summary

This study tests an experimental drug called REGN7041 in 72 people with active noninfectious uveitis, a condition causing inflammation inside the eye. The drug is an antibody designed to calm the immune system. Since this is the first time it's tested in humans, the main goal is to check safety and side effects. Researchers will also measure drug levels in blood and eye fluid, and see if the body makes antibodies against the drug.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
REGN7041 (an experimental antibody that targets immune cells)
What this could lead to
If successful, this could point toward a new treatment option for people with active noninfectious uveitis, potentially reducing eye inflammation without infection risk.
What could go wrong
This is a first-in-human study, so safety and effectiveness are unknown. The drug may cause side effects or not work as hoped. Results are early and may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

1 person

The number who actually took part.

Started

Dec 2025

Finished

Jul 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: 1. Diagnosis of non-infectious anterior, intermediate, posterior or panuveitis (For anterior uveitis, there must be evidence of inflammation affecting the posterior segment), as defined in the protocol 2. Active disease at baseline, as defined in the protocol 3. Part A only: Best Corrected Visual Acuity (BCVA) of ≤65 and \>10 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (Snellen equivalent of worse than or equal to 20/50 and better than 20/630) at the screening visit and on day 1 4. Part B only: BCVA of \<75 and \>10 ETDRS letters (Snellen equivalent of worse than 20/32 and better than 20/630) at the screening visit and on day 1 Key Exclusion Criteria: 1. BCVA of ≤30 ETDRS letters (Snellen equivalent of 20/250 or worse) at the screening visit and/or on day 1 2. Intraocular Pressure (IOP) \<5 mm Hg at the screening visit and/or on day 1 3. IOP \>25 mm Hg on day 1. Participants are permitted to take IOP-lowering eye drops 4. Confirmed or suspected infectious uveitis, as defined in the protocol NOTE: Other Protocol-Defined Inclusion/Exclusion Criteria Apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Active noninfectious uveitis affecting the posterior segment are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

idiopathic posterior uveitis panuveitis posterior uveitis uveitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Active noninfectious uveitis affecting the posterior segment

Contacts and locations

Locations

  • Illinois Retina Associates

    Oak Park, Illinois, 60304, United States

  • Retina Consultants of Texas

    Katy, Texas, 77494, United States

  • Retina Consultants of Texas - Houston

    Bellaire, Texas, 77401, United States

  • Retinal Consultants - Sacramento

    Sacramento, California, 95825, United States

  • Tennessee Retina

    Nashville, Tennessee, 37203, United States